Recent developments in the use of vitamin D analogues

Bibliography

• BIKLE DD, PILLAI S: Vitamin D, calcium, and epidermaldifferentiation. Endocr. Rev. (1993) 14:3–19.
   PubMed Web of Science ®Google Scholar
• ABE E, MIYAURA C, SAKAGAMI H et al.: Differentiationof mouse myeloid leukemia cells induced by la,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA (1981) 78:4990–4994.
   PubMed Web of Science ®Google Scholar
• NEMERE I, SCHWARTZ Z, PEDROZO H, SYLVIA VL, DEANDD, BOYAN BD: Identification of a membrane receptor for 1,25-Dihydroxyvitamin D3 which mediates rapid activation of protein kinase C. J. Bone Miner. Res. (1998) 13:1353–1359.
   PubMed Web of Science ®Google Scholar
• NORMAN AW: Receptors for la,25(011)2D3: past, present, future. J. Bone Miner. Res. (1998) 13:1360–1369.
   PubMed Web of Science ®Google Scholar
• BOUILLON R, OKAMURA WH, NORMAN AW: Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. (1995) 16:200–257.
   PubMed Web of Science ®Google Scholar
• VERSTUYF A, VERLINDEN L, VAN BAELEN H et al.: The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C- and D-rings. J. Bone Miner. Res. (1998) 13:549–558.
   Google Scholar
• VERSTUYF A, VERLINDEN L, VAN ETTEN E et al.:Biological activity of CD-ring modified la,25-dihydroxy vitamin D analogs: C-ring and five-membered D-ring analogs. J. Bone Mineral. Res. (2000) 15:237–252.
   Google Scholar
• BOEHM MF, FITZGERALD P, ZOU A: Novel nonsecoster-oidal vitamin D mimics exert VDR-modulating activi-ties with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem. Biol. (1999) 6:265–275.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrates bis-phenyl derivatives that mimics activities of 1,25(OH)2D.
   Google Scholar
• BOUILLON R, ALLEWAERT K, XIANG D-Z, TAN BK, VAN BAELEN H: Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity. J. Bone Miner. Res. (1991) 6:1051–1057.
   PubMed Web of Science ®Google Scholar
• BROWN A, SLATOPOLSKY E: Mechanisms for the selective actions of vitmain D analogs. In: Vitamin D. Feldman D, Glorieux FH, Pike JW (Eds.), Academic Press, San Diego, USA (1997):995–1009.
   Google Scholar
• VAN DEN BEMD GJCM, POLS HAP, BIRKENHAGER JC,VAN LEEUWEN JPTM: Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH 1060. Proc. Natl. Acad. Sci. USA (1996) 93:10685–10690.
   PubMed Web of Science ®Google Scholar
• CROFTS LA, HANCOCK MS, MORRISON NA, EISMAN JA:Multiple promoters direct the tissue-specific expres-sion of novel N-terminal variant human vitamin D receptor gene transcripts. Proc. Natl Acad. Sci. USA (1998) 95:10529–10534.
   PubMed Web of Science ®Google Scholar
• LIU YY, COLLINS ED, NORMAN AW, PELEG SP: Differen-tial interaction of la,25-dihydroxyvitamin D3 analogues and their 20-epi homologues with the vitamin D receptor. J. Biol. Chem. (1997) 272:3336–3345.
   PubMed Web of Science ®Google Scholar
• TAKEYAMA K, MASUHIRO Y, FUSE H: Selective interac-tion of vitamin D receptor with transcriptional coacti-vators by a vitamin D analog. Mol. Cell. Biol. (1999) 19:1049–1055.
   PubMed Web of Science ®Google Scholar
• LI YC, AMLING M, PIRRO AE et al.: Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology (1998) 139:4391–4396.
   PubMed Web of Science ®Google Scholar
• •This paper provides evidence of the skin as a direct vitamin D target tissue.
   Google Scholar
• VAN DE KERKHOF PCM: An update on vitamin D3 analogues in the treatment of psoriasis. Skin Pharmacol. Appl. Skin Physic)]. (1998) 11:2–10.
   PubMed Web of Science ®Google Scholar
• BARKER JN, ASHTON RE, MARKS R, HARRIS RI, BERTH-JONES J: Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br. J. Dermatol. (1999) 141:274–278.
   PubMed Web of Science ®Google Scholar
• DELANSORNE R, BONNET P, BOTELLA J et al.: Pharma-cological comparison between la,25(OH)2D3, calcipo-triol and TX 522. 10th workshop on vitamin D. Strasbourg, France (1997) Abstract 232.
   Google Scholar
• BRANDS S, BRAKMAN M, BOS JD, DE RIE MA: No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J. Am. Acad. Dermatol. (1999) 41:991–995.
   PubMed Web of Science ®Google Scholar
• PRYSTOWSKY JH, MUZIO PJ, SEVRAN S, CLEMENS TL:Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin D3) on vitamin D photosyn-thesis in patients with psoriasis. J. Am. Acad. Dermatol (1996) 35:690–695.
   PubMed Web of Science ®Google Scholar
• COURTOIS SJ, SEGAERT S, DEGREEF H, BOUILLON R,GARMYN M: Ultraviolet B suppresses vitamin D receptor gene expression in keratinocytes. Biochem. Biophys. Res. Commun. (1998) 246:64–69.
   PubMed Web of Science ®Google Scholar
• VAN DE KERKHOF PCM, CAMBAZARD F, HUTCHINSONPE et al.: The effect of addition of calcipotriol ointment (50 mg/g) to acitretin therapy in psoriasis. Br. J. Dermatol. (1998) 138:84–89.
   Google Scholar
• SEGAERT S, GARMYN M, DEGREEF H, BOUILLON R: Retinoic acid modulates the anti-proliferative effect of 1,25-dihydroxyvitamin D3 in cultured human epidermal keratinocytes. J. Invest. Dermatol. (1997) 109:46–54.
   PubMed Web of Science ®Google Scholar
• SEGAERT S, GARMYN M, DEGREEF H, BOUILLON R: Suppression of vitamin D receptor and upregulation of retinoid X receptor a expression during squamous differentiation of cultured keratinocytes. J. Invest. Dermatol. (2000) (In press).
   Google Scholar
• KANG S, LI X-X, DUELL EA: The retinoid X receptoragonist 9-cis-retinoic acid and the 24-hydroxylase inhibitor ketoconazole increase activity of 1,25-dihydroxyvitamin D3 in human skin in vivo. J. Invest. Dermatol. (1997) 108:513–518.
   PubMed Web of Science ®Google Scholar
• SCHUSTER I, ASTECKER N, EGGER H et al.: VitaminD-metabolism in human keratinocytes and biological role of products. In: Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone. Norman AW, Bouillon R, Thomasset M (Eds.) University of California, Printing and Reprographics, Riverside, CA, USA (1997):551–558.
   Google Scholar
• MILDE P, HAUSER U, SIMON T et al: Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J. Invest. Dermatol. (1991) 97:230–239.
   PubMed Web of Science ®Google Scholar
• THIERS B: The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. J. Am. Acad. Dermatol. (1997) 37:S69–S71.
   PubMedGoogle Scholar
• AOKI T, HASHIMOTO H, KOSEKI S, HOZUMI Y, KONDOS: la,24-dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in vivo and in vitro. Br. J. Dermatol (1998) 139:897–901.
   PubMed Web of Science ®Google Scholar
• GNIADECKI R, GNIADECKA M, SERUP J: Inhibition ofglucocorticoid-induced epidermal and dermal atrophy with KH 1060 - a potent 20-epi analogue of 1,25-dihydroxyvitamin D3. Br. J. Pharmacol. (1994) 113:439–444.
   PubMed Web of Science ®Google Scholar
• •These findings open perspectives for the use of vitamin D analogues for skin atrophy.
   Google Scholar
• JIMENEZ JJ, YUNIS AA: Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3. Cancer Res. (1992) 52:5123–5125.
   PubMed Web of Science ®Google Scholar
• HIDALGO M, RINALDI D, MEDINA G, GRIFFIN T, TURNERJ, VON HOFF DD: A Phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. AntiCancer drugs (1999) 10:393–395.
   PubMed Web of Science ®Google Scholar
• PARSAD D, SAINI R, VERMA N: Combination of PUVAsoland topical calcipotriol in vitiligo. Dermatology. (1998) 197:167–170.
   PubMed Web of Science ®Google Scholar
• •Promising results of vitamin D analogues of vitiligo.
   Google Scholar
• LEE J-H, YOUN JI: The photoprotective effect of1,25-dihydroxyvitamin D3 on ultraviolet light B-induced damage in keratinocytes and mechanism of action. J. Dermatol Sci. (1998) 18:11–18.
   PubMedGoogle Scholar
• EVANS SR, SCHWARTZ AM, SHCHEPOTIN El, USKOKOVIC M, SHCHEPOTIN IB: Growth inhibitory effects of 1,25-dihydroxyvitamin D3 and its synthetic analogue, lalpha,25-dihydroxy-16-ene-23yne-26,27-hexa fluoro-19-nor-cholecalcifero 1 (Ro 25-6760), on a human colon cancer xenograft. Clin. Cancer Res. (1998) 4:2869–2876.
   PubMed Web of Science ®Google Scholar
• FUJIOKA T, HASEGAWA M, ISHIKURA K, MATSUSHITA Y, SATO M, TANJI S: Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J. Urol. (1998) 160:247–251.
   PubMed Web of Science ®Google Scholar
• JAMES SY, MERCER E, BRADY M, BINDERUP L, COLSTON KW: EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol (1998) 125:953–962.
   PubMed Web of Science ®Google Scholar
• KOSHIZUKA K, KOIKE M, KUBOTA T, SAID J, BINDERUP L, KOEFFLER HP: Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int. Oncol. (1998) 13:421–428.
   PubMed Web of Science ®Google Scholar
• VANWEELDEN K, FLANAGAN L, BINDERUP L, TENNIS-WOOD M, WELSH J: Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology (1998) 139:2102–2110.
   PubMed Web of Science ®Google Scholar
• WILKERSON CL DARJATMOKO SR, LINDSTROM MJ, ALBERT DM: Toxicity and dose-response studies of 1,25(01)2-16-ene-23-yne vitamin D3 in transgenic mice. Clin. Cancer Res. (1998) 4:2253–2256.
   PubMed Web of Science ®Google Scholar
• YU WD, MCELWAIN MC, MODZELEWSKI RA et al.: Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J. Natl. Cancer Inst. (1998) 90:134–141.
   PubMed Web of Science ®Google Scholar
• ISEKI K, TATSUTA M, UEHARA H et al.: Inhibition of angiogenesis as a mechanism for inhibition by 1 alpha-hydroxyvitamin D3 and 1,25-dihydroxy vitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int. J. Cancer (1999) 81:730–733.
   PubMed Web of Science ®Google Scholar
• HERSHBERGER PA, MODZELEWSKI RA, SHURIN ZR, RUEGER RM, TRUMP DL, JOHNSON CS: 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Wafl/Cipl) in vitro and in vivo. Cancer Res. (1999) 59:2644–2649.
   PubMed Web of Science ®Google Scholar
• •In contrary to other papers, these authors describe a down regulation of p21 in vitro as well as in vivo by 1,25 (OH)2D.
   Google Scholar
• OINAM S, KARMAKAR R, ROY A, INDIRA BN, CHATTERJEE M: Effect of vitamin D3 on carcinogen-modified liver enzymes and tumour incidence in experimental rat mammary carcinogenesis. Eur. J. Cancer Prey. (1999) 8:159–168.
   PubMed Web of Science ®Google Scholar
• LOKESH WAR BL, SCHWARTZ GG, SELZER MG: Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemic)]. Biomarkers Prey. (1999) 8:241–248.
   PubMed Web of Science ®Google Scholar
• KOSHIZUKA K, KOIKE M, ASOU H eta].: Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer. Res. Treat. (1999) 53:113–120.
   Google Scholar
• KOSHIZUKA K, KUBOTA T, SAID J et al.: Combination therapy of a vitamin D3 analog and all-trans-retinoic acid: effect on human breast cancer in nude mice. AntiCancer Res. (1999) 19:519–524.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO H, IINO Y, KOIBUCHI Y eta].:Antitumor effect of 22-oxacalcitriol on estrogen receptor- negative MDA-MB-231 tumors in athymic mice. Oncol. Rep. (1999) 6:349–352.
   Google Scholar
• YUDOH K, MATSUNO H, KIMURA T: lalpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J. Lab. Clin. Med. (1999) 133:120–128.
   PubMedGoogle Scholar
• SABET SJ, DARJATMOKO SR, LINDSTROM MJ, ALBERT DM:Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors. Arch. OphthalmoL (1999) 117:365–370.
   PubMed Web of Science ®Google Scholar
• VINK-VAN WIJNGAARDEN T, POLS HAP, BUURMAN CJ: Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res. (1994) 54:5711–5717.
   PubMed Web of Science ®Google Scholar
• ABE-HASHIMOTO J, KIKUCHI T, MATSUMOTO T, NISHII Y, OGATA E, IKEDA K: Antitumor effect of 22-oxa-calcitriol, a noncalcaemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res. (1993) 53:2534–2537.
   PubMed Web of Science ®Google Scholar
• ANZANO MA, SMITH JM, USKOKOVIC MR et al.: lalpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluoro cholecalcitrio 1 (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. (1994) 54:1653–1656.
   PubMed Web of Science ®Google Scholar
• JAMES SY, MACKAY AG, COLSTON KW: Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J. Mol. Endocrinol. (1995) 14:391–394.
   PubMed Web of Science ®Google Scholar
• VERSTUYF A, MATHIEU C, VERLINDEN L, WAER M, TANBK, BOUILLON R: Differentiation induction of human leukemia cells (HL-60) by a combination of 1,25-dihydroxyvitamin D3 and retinoic acid (all trans or 9-cis). J. Steroid Biochem. Mol. Biol. (1995) 53:431–441.
   PubMed Web of Science ®Google Scholar
• JAMES SY, WILLIAMS MA, NEWLAND AC, COLSTON KW:Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. Gen. Pharmac. (1999) 32:143–154.
   PubMedGoogle Scholar
• BLUTT SE, ALLEGRETTO EA, PIKE JW, WEIGEL NL:1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocri-nology (1997) 138:1491–1497.
   PubMed Web of Science ®Google Scholar
• ZHAO XY, LY LH, PEEHL DM, FELDMAN D: Induction of androgen receptor by la,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology (1999) 140:1205–1212.
   PubMed Web of Science ®Google Scholar
• •In this paper an indirect effect of 1,25(OH)2D on the androgen receptor expression in LNCaP cells is demonstrated together with the additive effects of 9-cis retinoic acid. The synergistic effects of 1,25 (OH)2D and 9-cis retinoic acid on the inhibition of LNCaP cell proliferation is totally blocked by an androgen receptor antagonist.
   Google Scholar
• ABE J, NAKANO T, NISHII Y, MATSUMOTO T, OGATA E, IKEDA K: A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcaemia. Endocrinology (1991) 129:832–837.
   PubMed Web of Science ®Google Scholar
• RAVID A, ROCKER D, MACHLENKIN A et al.: 1,25-dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. (1999) 59:862–867.
   PubMed Web of Science ®Google Scholar
• MOFFATT KA, JOHANNES WU, MILLER GJ: la,25-dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prosate cancer cell lines. Clinical Cancer Res. (1999) 5:695–703.
   PubMed Web of Science ®Google Scholar
• BOLLAG W: Experimental basis of cancer combinationchemotherapy with retinoids, cytokines, 1,25-dihydroxyvitamin D3, and analogs. J. Cell Biochem. (1994) 56:427–435.
   PubMed Web of Science ®Google Scholar
• ROCKER D, RAVID A, LIBERMAN UA, GARACH-JEHOSHUA, KOREN R: 1,25-dihydroxyvitamin D3 potentiates the cytotoxic effects of TNF on human breast cancer cells. MoL Cell. EndocrinoL (1994) 106:157–162.
   PubMed Web of Science ®Google Scholar
• QUESADA JM, LOPEZ-LLUCH G, BURON MI: Ascorbateincreases the 1,25 dihydroxyvitamin D3-induced monocytic differentiation of HL-60 cells. Cakif Tissue Int. (1996) 59:277–282.
   PubMed Web of Science ®Google Scholar
• SOKOLOSKI JA, HODNICK, WF, MAYNE ST, CINQUINA C,KIM CS, SARTORELLI AC: Induction of the differentia-tion of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-KB. Leukemia (1997) 11:1546–1553.
   PubMed Web of Science ®Google Scholar
• SAITO Y, HATTA H, MANO Y, TAIRA N, SHIMIZU T, TAKEDA K: Vitamin D3 analogue K111060 combined with TPA synergistically induces mature macrophages in human myeloblastic leukemia ML-1 cells. AntiCancer Res. (1999) 19:1069–1076.
   PubMed Web of Science ®Google Scholar
• WANG X, GARDNER JP, KHEIR A, USKOKOVIC MR, STUDZINSKI GP: Synergistic induction of 11L60 cell differentiation by ketoconazole and 1-desoxy analogues of vitamin D3. J. Natl. Cancer Inst. (1997) 89:1199–1206.
   PubMed Web of Science ®Google Scholar
• DAWSON MI, CHAO WC, HOBBS PD, ZHANG X: Effects oftrans-retinoic acid, 9-cis-retinoic acid, la,25-(dihydroxy)vitamin D3 and a novel apoptosis-inducing retinoid on breast cancer and endothelial cell growth. Cancer Lett. (1998) 133:1–8.
   PubMed Web of Science ®Google Scholar
• OGATA E: The potential use of vitamin D analogs in thetreatment of cancer. Calcif. Tissue Int. (1997) 60:130–133.
   PubMed Web of Science ®Google Scholar
• ABDAIMI KE, PAPAVASILIOU V, RABBANI SA, RHIM JS,GOLTZMAN G, KREMER R: Reversal of hypercalcaemia with the vitamin D analogue EB 1089 in a human model of squamous cancer. Cancer Res. (1999) 59:3325–3328.
   PubMed Web of Science ®Google Scholar
• OSBORN JL, SCHWARTZ GG, SMITH D, BAHNSON R, DAYR, TRUMP DL: Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol. Oncol. (1995) 1:195–198.
   PubMedGoogle Scholar
• CROSS C, STAMEY T, HANCOCK S, FELDMAN D: Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D (calcitriol). J. Urology (1998) 159:2035–2040.
   PubMed Web of Science ®Google Scholar
• ZHAO XY, LY LH, PEEHL DM, FELDMAN D: lalpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology (1997) 138:3290–3298.
   PubMed Web of Science ®Google Scholar
• BOWER M, COLSTON KW, STEIN RC et al.: Topical calcipotriol treatment in advanced breast cancer: Lancet (1991) 337:701–702.
   Google Scholar
• GULLIFORD T, ENGLISH J, COLSTON K, SPROGEL P, COOMBES RC: A Phase I study of EB 1089, a vitamin D analogue. Proc. Am. Assoc. Cancer Res. (1996) 37:164
   Google Scholar
• GARLAND CF, COMSTOCK GW, GARLAND FC, FELSING K, SHAW EK, GORHAM ED: Serum 25-hydroxyvitamin D and colon cancer: 8-year prospective study. Lancet (1998) 2:1176–1178.
   Google Scholar
• JOHN EM, SCHWARTZ GG, DREON DM, KOO J: Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971-1975 to 1992. National health and nutrition examination survey. Cancer Epidemic)]. Biomarkers (1999) 8.399–406.
   PubMed Web of Science ®Google Scholar
• PEEHL DM: Vitamin D and prostate cancer risk. Eur. Urol. (1999) 35:392–394.
   PubMed Web of Science ®Google Scholar
• MILLER GJ: Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev. (1999) 17:353–360.
   Web of Science ®Google Scholar
• SPORN MB: New agents for chemoprevention of prostate cancer. Eur. Urology (1999) 35:420–423.
   PubMed Web of Science ®Google Scholar
• NIV Y, SPERBER AD, EIGER A et al: In colorectal carcinoma patients, serum vitamin D levels according to stage of the carcinoma. Cancer (1999) 86:391–397.
   PubMed Web of Science ®Google Scholar
• LIPKIN M, NEWMARK HL: Vitamin D, calcium and prevention of breast cancer: a review. J. Am. Coll. Nutr. (1999) 18:392S–397S.
   Google Scholar
• CASTEELS K, BOUILLON R, WAER M et al.: Prevention of Type I diabetes by late intervention with non-hypercalcaemic analogues of vitamin D3 in combination with cyclosporin A. Endocrinology (1998) 139:95–102.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, LAUREYS J, SOBIS H, VANDEPUTTE M, WAER M, BOUILLON R: 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes (1992) 41:1491–1495.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, WAER M, LAUREYS J, RUTGEERTS 0, BOUILLON R: Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia (1994) 37:552–558.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, WAER M, CASTEELS K, LAUREYS J, BOUILLON R: Prevention of Type I diabetes in NOD mice by non-hypercalcaemic doses of a new structural analogue of 1,25-(011)2D3, K111060. Endocrinology (1995) 136:866–872.
   PubMed Web of Science ®Google Scholar
• INABA M, NISHIZAWA Y, SONG K et al.: Partial protec-tion of la-hydroxyvitamin D3 against the develop-ment of diabetes induced by multiple low-dose streptozotocin injection in CD-1 mice. Metabolism (1992) 41:631–635.
   PubMed Web of Science ®Google Scholar
• FOURNIER C, GEPNER P, SADOUK M, CHARREIRE J: In vivo beneficial effects of cyclosporin A and 1,25-dihydroxyvitamin D3 on the induction of experi-mental autoimmune thyroiditis. Clin. ImmunoL Immunopathol (1990) 54:53–63.
   PubMedGoogle Scholar
• BRANISTEANU D, MATHIEU C, BOUILLON R: Synergism between sirolimus and in vitro and in vivo. J. Neuroim-munol (1997) 79:138–147.
   PubMed Web of Science ®Google Scholar
• LEMIRE JM, ARCHER DC: 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. (1991) 87:1103–1107.
   PubMed Web of Science ®Google Scholar
• BRANISTEANU D, WAER M, SOBIS H, MARCELIS S, VANDEPUTTE M, BOUILLON R: Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and la,25-(011)2D3. J. Neuroim-munol. (1995) 61:151–160.
   PubMed Web of Science ®Google Scholar
• LEMIRE JM, ARCHER DC, REDDY GS: 1,25-Dihydroxy-24-oxo-16ene-vitamin D3, a renal metabolite of the vitamin D analog 1,25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcaemia in vivo. Endocrinology (1994) 135:2818–2821.
   PubMed Web of Science ®Google Scholar
• GARCION E, SINDJI L, MONTERO-MENEI C, ANDRE C,BRACHET P, DARCY F: Expression of inducible nitric oxide synthase during rat brain inflammation: regula-tion by 1,25-dihydroxyvitamin D3. Glia (1998) 22:282–294.
   PubMed Web of Science ®Google Scholar
• LARSSON P, MATTSSON LKL, JOHNSSON C: A vitamin Danalogue (MC1288) has immunomodulatory proper-ties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin. Exp. Immunol (1998) 114:277–284.
   PubMed Web of Science ®Google Scholar
• LEMIRE JM: Immunomodulatory role of 1,25-dihydroxyvitamin D3. J. Cell. Biochem. (1992) 49:26–31.
   PubMed Web of Science ®Google Scholar
• KOIZUMI T, NAKAO Y, MATSUI T et al.: Effects ofcorticosteroid and 1,24R-dihydroxyvitamin D3 administration on lymphoproliferation and autoim-mune disease in MRL/MP lpr/lpr mice. Int. Arch. Allergy Appl. Immunol (1985) 77:396–404.
   PubMedGoogle Scholar
• ABE J, TAKITA Y, NAKANO T et al.: 22-Oxa-la-25-dihydroxyvitamin D3: a new synthetic analogue of vitamin D having a potent immunoregu-lating activity without inducing hypercalemia in mice. In: Calcium Regulation and Bone Metabolism. Cohn DV, Glorieux FH, Martin TJ (Eds.), Elsevier, Amsterdam, Nether-lands (1990):146–151.
   Google Scholar
• BRANISTEANU DD, LEENAERTS P, VAN DAMME B, BOUILLON R.: Partial prevention of active Heymann nephritis by la,25 dihydroxyvitamin D3. Clin. Exp. Immunol. (1993) 94:412–417.
   Google Scholar
• HATTORI M: Effect of la,25(011)2D3 on experimentalrat nephrotoxic serum nephritis. Nippon-Jinzo, Gakkai, Shi (1990) 32:147-159. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3)
   Google Scholar
• LILLEVANG ST, ROSENKVIST J, ANDERSEN CB, LARSEN S, KEMP E, KRISTENSEN T: Single and combined effects of the vitamin D analogue K111060 and cyclosporin A on mercuric-chloride-induced autoimmune disease in the BN rat. Clin. Exp. Immunol. (1992) 88:301–306.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, WAER M, LAUREYS J, RUTGEERTS 0, BOUILLON R: Activated form of vitamin D [1,25-(01)2D3] and its analogs are dose-reducing agents for cyclosporine in vitro and in vivo. Transplant. Proc. (1994) 26:3048–3049.
   PubMedGoogle Scholar
• CASTEELS K, WAER M, LAUREYS J et al.: Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation (1998) 65:1225–1232.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, LAUREYS J, WAER M, BOUILLON R: Preven-tion of autoimmune destruction of transplanted islets in spontaneously diabetic NOD mice by KH 1060, a 20-epi analog of vitamin D: synergy with cyclosporin. Transpl. Proc. (1994) 26:3128–3129.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, CASTEELS K, WAER M, LAUREYS J, VALCKX D, BOUILLON R: Prevention of diabetes recurrence after islet transplantation in NOD mice by analogues of 1,25(01)2D3 in combination with CyA. Transpl. Proc. (1997) 28:3095.
   Google Scholar
• LEMIRE JM, ARCHER DC, KHULKARNI A, INCE A, USKOKOVIC MR, STEPKOWSKI S: Prolongation of the survival of murine cardiac allografts by the vitamin D3 analogue 1,25-dihydroxy-delta16-cholecalciferol. Transplantation (1992) 54:762–763.
   PubMed Web of Science ®Google Scholar
• JORDAN SC, NIGATA M, MULLEN Y: 1,25-Dihydroxyvitamin D3 prolongs rat cardiac allograft survival. In: Vitamin D. Molecular, Cellular and Clinical Endocrinology. Norman AW, Schaefer K, Grigoleit HG et al. (Eds.), Walter de Gruyter, Berlin (1988):334–335.
   Google Scholar
• HULLETT DA, CANTORNA MT, REDAELLI C et al: Prolon-gation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation (1998) 66:824–828.
   PubMed Web of Science ®Google Scholar
• RAISANEN-SOKOLOWSKI AK, PAKKALA IS, SAMILA SP, BINDERUP L, HAYRY PJ, PAKKALA ST: A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation (1997) 63:936–941.
   PubMed Web of Science ®Google Scholar
• JORDAN SC, SHIBUKA R, MULLEN Y: 1,25-Dihydroxyvitamin D3 prolongs skin graft survival in mice. In: Vitamin D. Molecular, Cellular and Clinical Endocrinology Norman AW, Schaefer K, Grigoleit HG et al. (Eds.), Walter de Gruyter, Berlin (1988):346–347.
   Google Scholar
• VEYRON P, PAMPHILE R, BINDERUP L, TOURAINE JL: Two novel vitamin D analogues, KH 1060 and CB 966, prolong skin allograft survival in mice. Transpl. Immunol. (1993) 1:72–76.
   PubMedGoogle Scholar
• LEWIN E, OLGAARD K: The in vivo effect of a new, in vitro, extremely potent vitamin D3 analog KH 1060 on the suppression of renal allograft rejection in the rat. Calcite. Tissue InL (1994) 54:150–154.
   PubMed Web of Science ®Google Scholar
• JOHNSSON C, BINDERUP L, TUFVESON G: Immunosup-pression with the vitamin D analogue MC 1288 in experimental transplantation. Transpl. Proc. (1996) 28:888–891.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, BOUILLON R, RUTGEERTS 0, VANDEPUTTE M, WAER M: Potential role of 1,25(011) vitamin D3 as a dose-reducing agent for cyclosporine and FK 506. Transpl. Proc. (1994) 26:3130.
   PubMedGoogle Scholar
• FRAZAO JM, CHESNEY RW, COBURN JW: Intermittent oral lalpha-hydroxyvitamin Dy is effective and safe for the suppression of secondary hyperparathy-roidism in haemodialysis patients. lalphaD2 Study Group. Nephrol. Dial. Transplant. (1998) 13:68–67.
   PubMed Web of Science ®Google Scholar
• LLACH F, KESHAV G, GOLDBLAT MV et al.: Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin Dy. Am. J. Kidney Dis. (1998) 32:S48–S54.
   PubMed Web of Science ®Google Scholar
• SLATOPOLSKY E, DUSSO A, BROWN A: New analogs of vitamin D3. Kidney InL (1999) 56:S46–S51.
   Web of Science ®Google Scholar